Astria Therapeutics, Inc. (ATXS)

Market Cap	712.21M
Revenue (ttm)	n/a
Net Income (ttm)	-116.92M
Shares Out	56.43M
EPS (ttm)	-2.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,426,147
Open	12.30
Previous Close	12.25
Day's Range	12.27 - 12.64
52-Week Range	3.56 - 12.72
Beta	0.43
Analysts	Buy
Price Target	30.00 (+137.72%)
Earnings Date	Nov 12, 2025

About ATXS

Astria Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is navenibart, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in clinical development for the treatment of atopic dermatitis, an immune disorder assoc...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 25, 2015
• Employees: 78
• Stock Exchange: NASDAQ
• Ticker Symbol: ATXS
• Website: https://www.astriatx.com

Analyst Summary

According to 7 analysts, the average rating for ATXS stock is "Buy." The 12-month stock price target is $30.0, which is an increase of 137.72% from the latest price.

Price Target

$30.0

(137.72% upside)

Analyst Consensus: Buy